CD117, but Not Lysozyme, Is Positive in Cutaneous Plasmacytoma

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 12, 2003, Pages 1596-1598

  Bayer Garner, Ilene B ^a   Schwartz, Mary R ^b   Lin, Pei ^c   Smoller, Bruce R ^d  

^a MARSHFIELD CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; LYSOZYME; PARAFFIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

BONE MARROW; CANCER GRADING; CELL TYPE; CUTANEOUS PLASMACYTOMA; CYTOPLASM; FLOW CYTOMETRY; GRANULOCYTIC SARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOBLAST; PLASMA CELL; PLASMACYTOMA; PROTEIN EXPRESSION; REVIEW;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MURAMIDASE; PLASMACYTOMA; PROTO-ONCOGENE PROTEINS C-KIT; SARCOMA, GRANULOCYTIC; SKIN NEOPLASMS;

EID: 0345168070     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Boo K, Cheng S. A morphological and immunohistochemical study of plasma cell proliferative lesions. Malays J Pathol. 1992;14:45-48.
2. Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK, Harris NL. Plasma cell neoplasms. In: World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2001:142-150.
3. Sun NCJ, Fishkin BG, N es KM, Glassy EF, Carpentier C. Lymphoplasmacytic myeloma: an immunological, immunohistochemical and electron microscopic study. Cancer. 1979;43:2268-2278.
4. Durant JR, Barry WE, Learner N. The changing face of myeloma. Lancet. 1966;1:119-121.
5. Bayer-Garner IB, Joseph L, Sanderson RD, Smoller BR. Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytoma. J Cutan. 2003;30:18-22.
6. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000;156:791-795.
7. Longley BJ, Reguere MI, Yongsheng M. Classes of c-Kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25:571-576.
8. Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95:489-493.
9. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characteristics of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1665.
10. Lemoli RM, Fortuna A. C-kit ligand (SCL) in human multiple myeloma cells. Leuk Lymphoma. 1996;20:457-464.
11. Deo EA, Broo KJ. Serum lysozyme in multiple myeloma. J Lab Clin Med. 1977;90:899-903.
12. Al Safadi L, Hellerich U, Schaefer HE. The expression of lysozyme in multiple myeloma. Pathol Res Pract. 1994;190:578-583.
13. Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361-375.
14. Patterson JW, Parsons JM, White RM, Fitzpatrick JE, Kohout-Dutz E. Cutaneous involvement of multiple myeloma and extramedullary plasmacytoma. J Am Acad Dermatol. 1988;19:379-890.
15. Suwabe H, Serizawa A, Kajiwara H, Ohkido M, Tsutsumi Y. Degenerative processes of elastic fibers in sun-protected and sun-exposed skin: immunoelectron microscopic observation of elastin, fibrillin-1, amyloid P component, lysozyme, and alpha1-antitrypsin. Pathol Int. 1999;49:391-402.
16. Albrecht S, From L, Kahn HI. Lysozyme in abnormal dermal elastic fibers of cutaneous aging, solar elastosis and pseudoxanthoma elasticum. J Cutan Pathol. 1991;18:75-80.